MOTOR-ACTIVITY FOLLOWING THE ADMINISTRATION OF SELECTIVE D-1 AND D-2 DOPAMINERGIC DRUGS TO NORMAL COMMON MARMOSETS

被引:31
作者
LOSCHMANN, PA
SMITH, LA
LANGE, KW
JAEHNIG, P
JENNER, P
MARSDEN, CD
机构
[1] NATL HOSP,INST NEUROL,DEPT CLIN NEUROL,QUEEN SQ,LONDON WC1N 3BG,ENGLAND
[2] KINGS COLL,DIV BIOMED SCI,PHARMACOL GRP,PARKINSONS DIS SOC,EXPTL RES LABS,LONDON SW3 6LX,ENGLAND
[3] SCHERING AG,RES LABS,W-1000 BERLIN 65,GERMANY
[4] AFB COMSTAT GMBH BERLIN,EUROPACTR,W-1000 BERLIN 15,GERMANY
基金
英国惠康基金;
关键词
D-1; RECEPTORS; D-2; FUNCTIONAL INTERACTION; LOCOMOTOR ACTIVITY; COMMON MARMOSETS;
D O I
10.1007/BF02244422
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In normal common marmosets administration of the D-1/D-2 agonist apomorphine or the selective D-2 agonist quinpirole caused a dose-dependent increase in motor activity and induced stereotyped behaviour. Both the selective D-2 antagonist raclopride and the selective D-1 antagonist SCH 23390 inhibited normal locomotor activity and induced catalepsy. Quinpirole- and apomorphine-induced motor activity were potently inhibited by pretreatment with raclopride. The effects of quinpirole, but not apomorphine, were weakly inhibited by SCH 23390. The selective D-1 partial agonist SKF 38393 decreased motor activity and did not induce grooming, oral movements or other behaviours. SKF 38393 inhibited motor activity induced by the administration of quinpirole but did not alter apomorphine-induced motor behaviour. Locomotor activity in normal common marmosets appears to be mediated mainly via D-2 systems. In contrast to rodents, administration of SKF 38393 does not induce behavioural activation and there does not appear to be a facilitating effect of D-1 systems on D-2 function in the normal common marmoset. However, the ability of both SKF 38393 and SCH 23390 to inhibit quinpirole locomotor activity suggests some interaction between D-1 and D-2 systems to occur in this species.
引用
收藏
页码:303 / 309
页数:7
相关论文
共 26 条
[11]   DOPAMINERGIC BEHAVIOR STEREOSPECIFICALLY PROMOTED BY THE D1 AGONIST R-SK-AND-F-38393 AND SELECTIVELY BLOCKED BY THE D1 ANTAGONIST SCH-23390 [J].
MOLLOY, AG ;
WADDINGTON, JL .
PSYCHOPHARMACOLOGY, 1984, 82 (04) :409-410
[12]  
MOLLOY AG, 1987, PSYCHOPHARMACOLOGY, V92, P164
[13]   FURTHER EVIDENCE FOR 2 DIRECTIONS OF D-1-D-2 DOPAMINE RECEPTOR INTERACTION REVEALED CONCURRENTLY IN DISTINCT ELEMENTS OF TYPICAL AND ATYPICAL BEHAVIOR - STUDIES WITH THE NEW ENANTIOSELECTIVE D-2 AGONIST LY-163502 [J].
MURRAY, AM ;
WADDINGTON, JL .
PSYCHOPHARMACOLOGY, 1989, 98 (02) :245-250
[14]   THE INDUCTION OF GROOMING AND VACUOUS CHEWING BY A SERIES OF SELECTIVE D-1 DOPAMINE RECEPTOR AGONISTS - 2 DIRECTIONS OF D-1-D-2 INTERACTION [J].
MURRAY, AM ;
WADDINGTON, JL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 160 (03) :377-384
[15]  
Nomoto M, 1987, Mov Disord, V2, P37, DOI 10.1002/mds.870020105
[16]   THE D1 AGONIST SKF-38393 INHIBITS THE ANTIPARKINSONIAN ACTIVITY OF THE D2 AGONIST LY-171555 IN THE MPTP-TREATED MARMOSET [J].
NOMOTO, M ;
JENNER, P ;
MARSDEN, CD .
NEUROSCIENCE LETTERS, 1988, 93 (2-3) :275-280
[17]   THE DOPAMINE D2 AGONIST LY 141865, BUT NOT THE D1 AGONIST SKF 38393, REVERSES PARKINSONISM INDUCED BY 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) IN THE COMMON MARMOSET [J].
NOMOTO, M ;
JENNER, P ;
MARSDEN, CD .
NEUROSCIENCE LETTERS, 1985, 57 (01) :37-41
[18]  
OGREN SO, 1986, PSYCHOPHARMACOLOGY, V90, P287
[19]  
RIDLEY RM, 1979, BIOL PSYCHIAT, V14, P753
[20]  
RIDLEY RM, 1980, AMPHETAMINES RELATED, P97